Log in to save to my catalogue

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 2...

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 2...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2234822592

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

About this item

Full title

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Publisher

New York: Springer US

Journal title

Calcified tissue international, 2019-09, Vol.105 (3), p.271-284

Language

English

Formats

Publication information

Publisher

New York: Springer US

More information

Scope and Contents

Contents

Burosumab, a fully human monoclonal antibody to FGF23, is the only approved treatment for X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by renal phosphate wasting and substantial cumulative musculoskeletal morbidity. During an initial 24-week randomized, controlled trial, 134 adults with XLH received burosumab 1 mg/kg (
...

Alternative Titles

Full title

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2234822592

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2234822592

Other Identifiers

ISSN

0171-967X

E-ISSN

1432-0827

DOI

10.1007/s00223-019-00568-3

How to access this item